We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Syncona Limited | LSE:SYNC | London | Ordinary Share | GG00B8P59C08 | ORD NPV |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-1.00 | -0.81% | 123.00 | 123.20 | 124.40 | 123.00 | 123.00 | 123.00 | 32,110 | 08:26:35 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Trust,ex Ed,religious,charty | -39.79M | -56.02M | -0.0840 | -14.76 | 826.75M |
TIDMSYNC
RNS Number : 6764D
Syncona Limited
27 June 2019
Syncona Limited
Publication of 2019 Annual Report and Notice of Annual General Meeting
27 June 2019
Syncona Ltd, a leading healthcare company focused on founding, building and funding global leaders in life science, today announces that it has published its Annual Report and Accounts for the year ended 31 March 2019 ("2019 Annual Report"). In addition, Syncona has published its Notice of Annual General Meeting 2019 and a circular relating to the 2019 Dividend.
In compliance with Listing Rule 9.6.1, these documents have today been submitted to the National Storage Mechanism and will shortly be available for inspection at www.morningstar.co.uk/uk/nsm.
Copies of these documents, together with the Form of Proxy for use in connection with the 2019 Annual General Meeting, Charitable Allocation Form and Cash Election Form, are available electronically on Syncona's website at www.synconaltd.com/investors. Printed copies of these documents are also being posted to shareholders where requested.
Syncona's Annual General Meeting will be held at 10:30am on 30 July 2019 at the offices of Citco Fund Services (Guernsey) Limited, Arnold House, St Julian's Avenue, St Peter Port, Guernsey, GY1 3RD.
[ENDS]
Enquiries
Syncona Ltd
Siobhan Weaver / Annabel Clay
Tel : +44 (0) 20 3981 7940
FTI Consulting
Brett Pollard / Natalie Garland-Collins
Tel: +44 (0) 20 3727 1000
Copies of this press release and other corporate information can be found on the company website at: www.synconaltd.com
About Syncona
Syncona is a leading FTSE250 healthcare company focused on founding, building and funding global leaders in life science. Our vision is to deliver transformational treatments to patients in truly innovative areas of healthcare while generating superior returns for shareholders.
We seek to partner with the best, brightest and most ambitious minds in science to build globally competitive businesses.
We take a long-term view, underpinned by a deep pool of capital, and are established leaders in gene and cell therapy. We focus on delivering dramatic efficacy for patients in areas of high unmet need.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
ACSUBSRRKRANUAR
(END) Dow Jones Newswires
June 27, 2019 06:44 ET (10:44 GMT)
1 Year Syncona Chart |
1 Month Syncona Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions